Pharmaceutical manufacturers of Lamotrigine

TAPI stands as the primary global provider of active pharmaceutical ingredients (APIs). With the most extensive range of over 370 high-caliber API products in the industry, we cater to almost 1,000 clients across more than 100 nations. Operating as an independent division under Teva Pharmaceutical Industries, our legacy in the generic API sector spans over 80 years. Situated in close proximity to Tel Aviv, Israel, TAPI boasts a workforce of over 5,000 professionals spread across 19 facilities worldwide. Our cutting-edge manufacturing plants are situated in Italy, Hungary, the Czech Republic, Croatia, Israel, India, China, Mexico, and several other locations.

Unichem Laboratories was founded in 1944 by Late Mr. Amrut Mody, a pioneer in the Indian pharmaceuticals business. With a rich tradition of unwavering quality and reliability, Unichem brings together a unique blend of modern, value-added research and deep knowledge of the Indian pharmaceuticals industry.ç

Polpharma Group serves as a top-tier pharmaceutical manufacturer in Europe and a reliable partner for pharmaceutical firms globally. With a wide range of products (Rx, CHC, APIs), expert services, and competencies across the value chain, along with extensive knowledge of local CEE/CIS markets, it provides distinct growth opportunities for B2B partners. Collaborating with Polpharma Group offers access to a supportive environment, guidance from skilled professionals, and cutting-edge resources. The company actively seeks partners across various areas of operation, from product development and production to commercial cooperation. Additionally, Polpharma API, a Poland-based CDMO specializing in active pharmaceutical ingredients (APIs), stands as a significant European API supplier, catering to pharmaceutical companies worldwide. The company is in the process of a $45 million manufacturing expansion, incorporating HPAPI and cryogenic technologies, with investments in a pilot plant and R&D capabilities. Operations are set to expand from mid-2023, with full completion expected by 2026.

Founded in 1986 by Mr. P. V. Ramprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born of a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares on the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and anti-biotics, among others.

Teva's roots are deeply rooted in the land of Israel since 1901 in Jerusalem. That's when the first chapter was written in the long and unique history of the company, which slowly transformed from a small drug trading house to the largest generic company in the world, improving the health of millions of patients in Israel and around the world every day.

Alembic Pharmaceuticals Limited is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities. Headquartered in Vadodara, Gujarat, we derive a third of our revenue of over $600 million from the India market.

Optimus is one of the fastest-growing pharmaceutical companies with 16 years of experience in providing the best quality of API, Intermediates & Finished formulations in Global markets. Our aim from day one has been to provide and ensure better healthcare across the globe through our research, Innovations, affordable products & manufacturing excellence. Sekhmet Pharmaventures acquired major stake in Optimus Drugs Group of Companies in May 2022.

The Zydus group is based in Ahmedabad, India, and is placed 4th in the Indian pharmaceutical sector. Zydus' global operations have a substantial presence in the regulated markets of the US, Europe (specifically France and Spain), and in the prominent markets of Latin America and South Africa. It also has a significant presence in 25 other developing markets around the world.

Bringing 86 years of expertise, UQUIFA'S operational approach is built on a fusion of a high-quality production platform and a proven history of service and dependability. UQUIFA specializes in the production of Active Pharmaceutical Ingredients (APIs), Intermediates, and RSM's for the pharmaceutical and animal health sectors on a global scale. The organization runs 2 production facilities (located in Spain and Mexico) with stringent compliance to all regulatory standards. These facilities operate under cGMP conditions and have undergone evaluation and endorsement from prominent global pharmaceutical companies.

VIATRIS™ represents a fresh approach to healthcare, dedicated to ensuring medicine accessibility, promoting sustainable practices, pioneering creative remedies, and enhancing patient results. Founded in 2020 through the merger of Mylan and Upjohn, Viatris unites top-notch scientific, production and distribution skills with established regulatory, medical and commercial proficiencies.

Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring For Life has always been and continues to remain, our guiding purpose. Driven by the same purpose, we have extended our presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, we are deepening our presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of Caring for Life and deep-rooted community links wherever it is present, make it a partner of choice for global health bodies and stakeholders.

For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others.

Jubilant Ingrevia Limited is an internationally integrated provider of Life Science products and Innovative Solutions, catering to Pharmaceutical, Nutrition, Agrochemical, Consumer, and Industrial clients with tailored products and solutions that are pioneering, cost-efficient, and adhere to outstanding quality standards. Its range also encompasses personalized research and production for pharmaceutical and agrochemical customers on an exclusive basis. The organization provides a selection of over 125 products & pioneering solutions utilizing more than 35 essential chemistry and technology platforms across its three business segments of Speciality Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. With a team of over 2,100 employees serving more than 1,500 customers in over 50 countries worldwide, the company is motivated to bring value to millions of lives through innovations and state-of-the-art technology. For more information, please visit www.jubilantingrevia.com. Business Segments: Speciality Chemicals consists of distinct building blocks such as Pyridine and Picolines, Cyanopyridines, Piperidine, and their value-added derivatives. The company has recently ventured into Diketene Chemistry, currently producing Diketene esters & amide with several other Diketene derivatives in the pipeline. The Speciality Chemicals products are utilized in the production of a variety of Agrochemicals, Pharmaceuticals, Nutrition, Fine chemicals, Oilfield chemicals, Electronics, and Solvents. Nutrition & Health Solutions caters to Human & Animal Nutrition, Pharmaceutical & Personal Care segment/applications and comprises three businesses - Nutrition & Health Ingredients, Animal Nutrition & Health Solutions, and Human Nutrition & Health Solutions. Chemical Intermediates manufactures a range of Chemical Intermediates including Acetyl Products and Speciality Ethanol.

SMS Lifesciences India Limited, headquartered in Hyderabad, India, is a research-driven company with over three decades of experience. It is a public listed leading API manufacturer, supplying to major generic and innovator firms. With a focus on APIs, the company operates four state-of-the-art facilities and provides quality alternative manufacturing solutions to multinational companies for their contract research and manufacturing needs. The company has multiple manufacturing facilities supporting a wide range and capacity of APIs and Intermediates.

Established in 1973 and based in Mumbai, India, Alkem started its operations as a healthcare marketing firm. Alkem is a major participant in the market for branded and generic drugs in India. The company has a strong presence in various therapeutic segments such as Anti-infective, Gastro-intestinal, Pain Management, Vitamins/Minerals/Nutritions, Central Nervous System, Anti-diabetic, Anti-osteoporosis, Anti-malarial, Cardiovascular, Immunosuppressants, and Nutraceutical segment.

Hua Hai Pharmaceutical Co., Ltd. is a leading Chinese pharmaceutical company offering a comprehensive range of products and services. They specialize in the production of active pharmaceutical ingredients (APIs) and finished dosage forms, including tablets, capsules, injectables, and oral solutions. Their product portfolio addresses various therapeutic areas such as cardiovascular health, anti-infectives, and central nervous system disorders. The company is committed to innovation through significant investment in research and development, aiming to discover new treatments and enhance existing ones. With state-of-the-art manufacturing facilities adhering to international quality standards, Hua Hai Pharmaceutical is dedicated to delivering high-quality and effective pharmaceutical solutions to global markets.

Medichem is a vertically integrated pharmaceutical company. We specialize in the development and manufacture of APIs and FDFs for the global generics industry. Our portfolio includes around 45 APIs and 20 FDFs, and we are a world leader in Chlorhexidine products. With nearly half a century of industry experience, we guarantee the highest standards of quality, operational excellence and respect for the environment. Medichem is headquartered in Spain, with a team of around 400 talented individuals in locations including the USA, Malta and China. We serve over 600 corporate customers in more than 60 countries worldwide.

Polepharma has been organizing and advancing the pharmaceutical industry in France, specializing in the biopharmaceutical sector for two decades. It has developed into the leading European hub for drug production, facilitating collaboration between excellence centers and industry stakeholders. Polepharma is committed to three collective principles, including the bold ambition to position France as the global leader in pharmaceutical development. On the other hand, Polpharma is a prominent CDMO and API producer based in Poland. With over 70 years of expertise, it stands as the largest API manufacturer in Poland, offering a comprehensive range of materials from clinical quantities to market supply. The company has fully integrated its operations, covering R&D to manufacturing, to provide cost-effective and timely solutions to its clients. Furthermore, Polpharma has made significant investments to enhance its API plant in Starogard Gdanski, incorporating HPAPI and cryogenic technologies, along with a pilot plant and R&D capabilities.